Ipamorelin/CJC1295 5mg Canada

Technical Specifications

Product Name: Ipamorelin/CJC1295
Total Peptide Content: 5mg per vial
Components: Ipamorelin / CJC-1295 (modified GRF analogue, non-DAC format unless otherwise specified)
Format: Lyophilized peptide blend
Purity Standard: ≥98% (individual components, batch dependent)
Research Classification: Investigational peptide blend – laboratory research use only

Ipamorelin/CJC1295 5mg Canada is supplied as a lyophilized dual-peptide formulation intended exclusively for laboratory and analytical applications. Each vial contains 5 milligrams of a synthetic peptide mixture of Ipamorelin and CJC-1295.

This product is classified as an investigational research compound and is not authorized for therapeutic, diagnostic, or consumer use in Canada.

Research Overview

Ipamorelin/CJC1295 5mg Canada combines two peptides frequently studied in endocrine and growth hormone signalling research. Ipamorelin is a selective growth hormone secretagogue that acts on the ghrelin (GHS-R1a) receptor. CJC-1295 is a modified analogue of growth hormone–releasing hormone (GHRH) designed to enhance stability in experimental systems.

In laboratory settings, these peptides are often examined for their independent and complementary roles in stimulating growth hormone release through distinct receptor pathways. Scientific literature describes Ipamorelin as a ghrelin receptor agonist and CJC-1295 as a GHRH receptor agonist, both acting at the anterior pituitary in controlled research models.

Research involving Ipamorelin/CJC1295 5mg Canada typically focuses on pulsatile hormone secretion patterns, receptor signalling cascades, and downstream activation of endocrine pathways in vitro and in animal studies. Comparative analyses may explore differences in receptor binding, signal amplification, and pharmacokinetic behaviour under controlled conditions.

All descriptions of hormonal pathways reflect investigational research findings and do not imply authorized medical or therapeutic application.

Mechanism Overview

In laboratory models, ipamorelin functions as a selective agonist at the growth hormone secretagogue receptor (GHS-R1a), which is also activated by the endogenous peptide ghrelin. Activation of this receptor stimulates intracellular signalling pathways that promote growth hormone release in experimental systems.

CJC-1295, as a modified GHRH analogue, binds to the growth hormone–releasing hormone receptor (GHRHR) in the anterior pituitary. Receptor activation leads to increased cyclic AMP production and subsequent growth hormone secretion in research models.

When combined as Ipamorelin/CJC1295 5mg Canada, the peptides are studied for their interactions with both the ghrelin and GHRH receptor pathways—researchers analyze receptor synergy, pulse amplitude modulation, and downstream signalling markers in controlled laboratory environments.

Mechanistic explanations remain confined to preclinical and investigational data and are presented for educational purposes only.

Clinical Development Context

Both Ipamorelin and CJC-1295 have been evaluated in early-stage clinical research investigating endocrine physiology and growth hormone dynamics. Published literature includes pharmacokinetic and pharmacodynamic studies conducted under regulated research conditions.

Despite this research activity, Ipamorelin/CJC1295 5mg, supplied in research-grade format, is categorized strictly as an investigational laboratory compound. It is distinct from any authorized pharmaceutical preparation and is not approved by Health Canada for prescription or consumer use.

Ongoing scientific interest in growth hormone secretagogues and GHRH analogues continues within academic and clinical research institutions.

Regulatory Status in Canada

Ipamorelin/CJC1295 5mg Canada is classified as an investigational research peptide blend. Health Canada does not authorize it as a therapeutic drug, natural health product, or over-the-counter medication.

The peptides within Ipamorelin/CJC1295 5mg Canada are supplied exclusively for laboratory and analytical purposes. They are not intended for human or veterinary administration.

Handling, storage, and study of Ipamorelin/CJC1295 5mg in Canada must comply with applicable federal and provincial Canadian regulations governing chemical and biological research materials. Research institutions and laboratories are responsible for ensuring regulatory compliance.

Molecular and Structural Notes

Ipamorelin is a synthetic pentapeptide with a molecular weight of approximately 711.9 g/mol. Its structure includes modifications designed to enhance selectivity for the GHS-R1a receptor in experimental systems.

CJC-1295 is a modified 29-amino-acid analogue of GHRH with amino acid substitutions that improve resistance to enzymatic degradation in vitro. Non-DAC forms lack the albumin-binding Drug Affinity Complex modification found in DAC variants.

Ipamorelin/CJC1295 5mg Canada is typically characterized using analytical techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to confirm identity and purity of each component before blending.

The lyophilized format supports peptide stability during storage when maintained under appropriate laboratory conditions.

Frequently Asked Questions

What is Ipamorelin/CJC1295 5mg Canada studied for in research?
Ipamorelin/CJC1295 5mg Canada is studied in laboratory settings to investigate growth hormone receptor signalling and endocrine pathway modulation.

Is Ipamorelin/CJC1295 approved for medical use in Canada?
No. Health Canada does not authorize ita for therapeutic or consumer use in research-grade form.

What type of product is the 5mg Canada Ipamorelin/CJC1295?
It is an investigational dual-peptide blend intended solely for laboratory research.

Does Ipamorelin/CJC1295 5mg Canada contain additives?
Unless specified in the batch documentation, the vial contains only the lyophilized peptide components.

Can Ipamorelin/CJC1295 5mg Canada be used outside research facilities?
No. It is supplied exclusively for controlled laboratory and analytical research applications.

Educational Disclaimer

Ipamorelin/CJC1295 5mg Canada is an investigational peptide blend supplied solely for laboratory and analytical use. Health Canada does not approve it as a medication, therapeutic agent, or consumer product.

Information provided on this page is educational in nature and based on publicly available scientific literature describing investigational research contexts. No medical, diagnostic, or therapeutic claims are made.

Study and handling of Ipamorelin/CJC1295 5mg Canada should occur only within properly equipped research facilities and in accordance with applicable Canadian regulations and institutional guidelines.